top of page

Nobel laureate Carolyn Bertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates

Firefly Bio emerged from stealth yesterday with a $94M series A. Co-Founder Carolyn Bertozzi introduces the company and explains the idea behind combining the science of antibody-drug conjugates with protein degraders.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

KH_Logo_Horizontal_Tagline_Black-1.png

Klein Hersh is a precision executive search firm with over 25 years of proven success partnering with clients to deliver the visionary leaders shaping the future of life sciences and healthcare. We believe that the innovation behind a healthier world starts with bringing the best and brightest minds together. Our experienced team of dedicated experts is deeply immersed in every facet of pharma, biotech, and healthcare, and has developed trusted relationships with far-reaching talent networks.

bottom of page